摘要
目的:探讨低剂量延时静脉滴入吉西他滨联合顺铂方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效和安全性。方法:60例ⅢB～Ⅳ期NSCLC患者随机分为治疗组(30例)和对照组(30例)。治疗组采用吉西他滨低剂量延时静脉滴入联合顺铂方案治疗:吉西他滨250mg/m2加入500mL生理盐水,6h持续静脉滴入,d1、d8;顺铂75mg/m2加入500mL生理盐水,d1、d3,每21d重复。对照组治疗方案:吉西他滨1000mg/m2加入100mL生理盐水,30min静脉滴入,d1、d8;顺铂75mg/m2加入500mL生理盐水,d1、d3,每21d重复。治疗周期结束后评价近期疗效、观察毒副反应,随访1年评价客观疗效和生存率。结果:治疗组近期临床疗效有效率为40.0%,高于对照组(36.7%),但两组比较差异无统计学意义,P>0.05;治疗组1年生存率、平均随访时间和中位疾病进展时间显著高于对照组,差异均有统计学意义,P<0.05;两组白细胞、血红蛋白、血小板毒性与非血液系统毒性之间差异无统计学意义(P<0.05),但治疗组Ⅲ～Ⅳ度的白细胞、血小板毒性和恶心、呕吐发生率低于对照组,差异有统计学意义,P<0.05。结论:低剂量延时静脉滴入吉西他滨联合顺铂方案治疗晚期NSCLC临床疗效肯定,毒副反应小,值得临床推广。
OBJECTIVE：To evaluate and compare the efficacy and toxieity in advanced non-small cell lung cancer（NSCLC） patients treated by delayed infusion of low dose gemcitabine combined with cisplatin maintenance chemotherapy regimens. METHODS： A total of 60 cases of ⅢB-Ⅳ stage NSCLC patients were randomly divided into treatment group （n=30） and control group （n=30）. The treatment group was given the treatment of delayed infusion of low dose gemcitabine combined with cisplatin maintenance chemotherapy regimens： 250 mg/m2 gemcitabine in 500 mL NS, iv drip for 6 h, d1,d8;75 mg/m2 cisplatin in 500 mL NS, d1,d3, 21 days as 1 cycle. The control group was given the treatment of conventional dose gemcitabine combined with cisplatin maintenance chemotherapy regimens： 1 000 mg/m2 gemcitabine in 100 mL NS, iv drip for 30 min, d1,d8;75 mg/m2 cisplatin in 500 mL NS, d1,d3, 21 days as 1 cycle. After treatment the short-term efficacy and toxieity were evaluated, followed up for 1-year the objective response and the survival rate were evaluated. RESULTS： The short-term efficacy rate of the treatment group was 40.0%, which was higher than the control group, but no significant difference between the two groups （P0.05）. The 1 year survival rate, the mean time and median disease progression time of the treatment group were significantly higher the control group （P0.05）. The white blood cells, hemoglobin, platelet toxicity and non-hematologic toxicity were no significant difference between the two groups （P0.05）, but the Ⅲ-Ⅳ degree of white blood cell and platelet toxicity of the treatment group were lower than the control group, the nausea and vomiting of the treatment group were lower than the control group, compared with the control group the difference was significant （P0.05）. CONCLUSION： The delayed infusion of low dose gemcitabine combined with cisplatin maintenance chemotherapy regimens for treatment of advanced NSCLC patients have better efficacy and lower toxieity,and the therapy method is worthy to be popularized.
出处
《中华肿瘤防治杂志》
CAS
2010年第19期1568-1570,共3页
Chinese Journal of Cancer Prevention and Treatment
